BETTA PHARMACEUTICALS(300558.SZ)

Last Updated 00:00:00
longbridge loading

BETTA PHARMACEUTICALS: The company currently does not have exclusive agency for foreign products

Zhitong·
HK
贝达药业
0.00%
SZ
300558
+0.25%
Zhitong·
HK
贝达药业
0.00%
SZ
300558
+0.25%

A-share innovative drug concept stocks fluctuated lower, with BETTA PHARMACEUTICALS falling over 10%, Jincheng Pharm, Konruns, Baillie Tianheng, Olymvax Biopharmaceuticals, and CCHT all dropping more than 5%

Zhitong·
SZ
300233
-0.93%
SZ
000661
-2.77%
SZ
300558
+0.25%
Zhitong·
SZ
300233
-0.93%
SZ
000661
-2.77%
SZ
300558
+0.25%

BETTA PHARMACEUTICALS: Will strive for more new drug approvals in high-incidence tumor areas such as lung cancer and breast cancer

Wallstreetcn·
SZ
300558
+0.25%
HK
贝达药业
0.00%
Wallstreetcn·
SZ
300558
+0.25%
HK
贝达药业
0.00%

BETTA PHARMACEUTICALS: The first prescription for Enasidenib Hydrochloride Capsules has been issued in the United States

Zhitong·
HK
贝达药业
0.00%
SZ
300558
+0.25%
Zhitong·
HK
贝达药业
0.00%
SZ
300558
+0.25%

BETTA PHARMACEUTICALS: Clinical research on the postoperative adjuvant indication of ensartinib has made progress

Zhitong·
HK
贝达药业
0.00%
SZ
300558
+0.25%
Zhitong·
HK
贝达药业
0.00%
SZ
300558
+0.25%

BETTA PHARMACEUTICALS: Currently, there is no need to provision for the issuance loss of Heyuan Biotechnology

Zhitong·
SZ
300558
+0.25%
HK
贝达药业
0.00%
Zhitong·
SZ
300558
+0.25%
HK
贝达药业
0.00%

BETTA PHARMACEUTICALS released its performance for the first half of the year, with a net profit attributable to the parent company of 140 million yuan, a decrease of 37.53%

Zhitong·
HK
贝达药业
0.00%
SZ
300558
+0.25%
Zhitong·
HK
贝达药业
0.00%
SZ
300558
+0.25%

BETTA PHARMACEUTICALS: MCLA-129 is currently exploring indications in the field of lung cancer

Zhitong·
SZ
300558
+0.25%
HK
贝达药业
0.00%
Zhitong·
SZ
300558
+0.25%
HK
贝达药业
0.00%

BETTA PHARMACEUTICALS: The company has corresponding preclinical project establishment for the KRAS target

Zhitong·
SZ
300558
+0.25%
HK
贝达药业
0.00%
Zhitong·
SZ
300558
+0.25%
HK
贝达药业
0.00%

BETTA PHARMACEUTICALS: Has reached a strategic cooperation with Boryung Biopharma, and the company’s exclusive distribution of Anruize has officially launched nationwide sales

Zhitong·
HK
贝达药业
0.00%
SZ
300558
+0.25%
Zhitong·
HK
贝达药业
0.00%
SZ
300558
+0.25%
© 2026 Longbridge｜Disclaimer